*Cost-Benefit Analysis Cystectomy/*economics/*methods Humans *Laparoscopy *Robotic Surgical Procedures Urinary Bladder Neoplasms/*economics/*surgery

*DNA Methylation Disease Progression Female Genes APC/*physiology Humans Male *Promoter Regions Genetic *Urinary Bladder Neoplasms/genetics/pathology/urine

Cystectomy/*methods Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology Prospective Studies Recovery of Function Retrospective Studies Standard of Care Urinary Bladder Neoplasms/rehabilitation/*surgery bladder cancer enhanced recovery after surgery meta-analysis postoperative rehabilitation radical cystectomy

Adolescent Adult Aged Aged 80 and over Animals Cultured Milk Products *Dairy Products *Diet Dietary Fats/administration & dosage *Feeding Behavior Female Humans Male Middle Aged Milk *Urinary Bladder Neoplasms/etiology/prevention & control Young Adult dairy products fermented dairy products whole milk bladder cancer meta-analysis systematic review

*Cystectomy/adverse effects/methods Humans Neoplasm Staging Neoplasm Residual/pathology/surgery *Reoperation/methods/statistics & numerical data *Urinary Bladder Neoplasms/pathology/surgery Cystoscopy Meta-analysis Neoplasm recurrence Urinary bladder neoplasms

Female Humans Male Prospective Studies *Quality of Life Urinary Bladder Neoplasms/drug therapy/*psychology/radiotherapy Bladder cancer Chemotherapy Muscle-invasive bladder cancer Quality of life Urothelial cancer PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Body mass index diet dietary supplements prognosis urinary bladder cancer

Urinary bladder cancer characteristics prognosis review conflicts of interest with respect to the research authorship and/or publication of this article.

Biopsy/methods Carcinoma in Situ/*pathology/*therapy Humans Muscle Smooth Neoplasm Invasiveness Urinary Bladder Neoplasms/*pathology/therapy Biopsias aleatorias de vejiga Carcinoma in situ Non-muscle invasive bladder cancer Random bladder biopsies Tumor vesical no-músculo invasivo

Bacille Calmette-Guérin Nmibc gemcitabine intravesical therapy meta-analysis non-muscle invasive bladder cancer

Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

bladder tumor childhood exposure environmental smoking nonsmoking adult

*Cystectomy *Health Status Humans Patient Education as Topic/*methods Preoperative Care/*methods Relaxation Therapy/*methods Urinary Bladder Neoplasms/*surgery Bladder cancer Cystectomy Supportive intervention Systematic review PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Circulating Tumor DNA/*analysis/blood/urine Humans Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/pathology CfDNA biomarkers diagnosis meta-analysis

bladder cancer hydronephrosis lymph node invasion stage survival

Cystectomy/*methods Humans *Robotic Surgical Procedures Treatment Outcome Urinary Bladder Neoplasms/*surgery Oncologic outcome Open radical cystectomy Positive surgical margin Robot-assisted radical cystectomy

Aminolevulinic Acid/*chemistry Cystoscopy/methods Humans Image Interpretation Computer-Assisted/*methods Narrow Band Imaging/methods Photosensitizing Agents/*chemistry Urinary Bladder Neoplasms/metabolism/pathology/*surgery Narrow band imaging bladder cancer diagnostic performance photodynamic diagnosis white light-guided cystoscopy

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Periodontal diseases cohort studies meta-analysis periodontitis urinary bladder neoplasms